Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
03:02pm, Thursday, 06'th Oct 2022 Zacks Investment Research
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
01:00pm, Thursday, 06'th Oct 2022 Zacks Investment Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
10:32am, Thursday, 06'th Oct 2022
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
01:45pm, Wednesday, 05'th Oct 2022 Zacks Investment Research
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
What Happened In The Stock Market Today & 4 Penny Stocks To Watch
01:41am, Wednesday, 05'th Oct 2022 PennyStocks
What happened in the stock market on Tuesday October 4 and what to watch with penny stocks this week
The post What Happened In The Stock Market Today & 4 Penny Stocks To Watch appeared first on Penny
These Were The Five Best And Worst Performing Mega-Cap Stocks In September 2022
08:02pm, Tuesday, 04'th Oct 2022
September has historically been the weakest month for the U.S. stock market, and 2022 was no different.
The Short List Of Dow Jones Stocks That Are Actually Up This Year: Hint — It's Very Short
09:56pm, Monday, 03'rd Oct 2022 Benzinga
The stock market has had a rough going for the first nine months of the year in 2022. All the major indexes are down year-to-date, including the Dow Jones Industrial Average.
Here’s a look at the fo
Merck (MRK) Gains But Lags Market: What You Should Know
09:45pm, Monday, 03'rd Oct 2022 Zacks Investment Research
Merck (MRK) closed at $87.55 in the latest trading session, marking a +1.66% move from the prior day.
Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?
01:12pm, Monday, 03'rd Oct 2022 Zacks Investment Research
Bristol Myers (BMY) expects recent drug approvals to generate an incremental stream of revenues and combat competition for its key drugs.
Dividend Champion, Contender, And Challenger Highlights: Week Of October 2
05:33am, Sunday, 02'nd Oct 2022 Seeking Alpha
Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Click here to see companies with upcoming ex-dividend dates and upcoming pay dates.
What This News Means for Merck
02:30pm, Saturday, 01'st Oct 2022 The Motley Fool
Cancer drug Lynparza received an approval in China to treat patients with a type of ovarian cancer.
What This News Means for Merck
10:30am, Saturday, 01'st Oct 2022
Cancer drug Lynparza received an approval in China to treat patients with a type of ovarian cancer.
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
02:10pm, Friday, 30'th Sep 2022 Benzinga
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock.
When asked about
10 Analysts Have This to Say About Merck & Co
12:31pm, Friday, 30'th Sep 2022 Benzinga
Merck & Co (NYSE:MRK) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
6
3
0
0
Last 30D
0
1
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
06:45am, Thursday, 29'th Sep 2022
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2022 sales and earnings conference call with institutiona
